What is the recommended dose of tazosin (doxazosin) for a patient with severe impaired renal function, defined as a glomerular filtration rate (GFR) less than 30 mL/min, for intravenous (IV) administration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Doxazosin Dosing in Severe Renal Impairment

No dose adjustment of doxazosin is required for patients with severe renal impairment (GFR <30 mL/min), as the pharmacokinetics remain unchanged regardless of renal function.

Pharmacokinetic Evidence

  • Doxazosin pharmacokinetics are not significantly altered by renal impairment, with no significant relationship between plasma elimination half-life or area under the curve (AUC) and degree of renal dysfunction 1, 2.

  • Studies demonstrate that plasma elimination half-life, AUC, and total clearance of doxazosin remain similar in patients with normal renal function compared to those with impaired renal function, including severe impairment 2, 3.

  • The drug can be used effectively at similar doses in both normal and impaired renal function without requiring adjustment 3.

Dosing Recommendations

  • Start with 1 mg daily and titrate upward by doubling the dose every 2 weeks based on blood pressure response 1.

  • Average effective doses range from 2-16 mg daily, with studies showing mean doses of 5.6 mg/day achieving adequate blood pressure control in chronic renal failure patients 4.

  • Higher doses can be safely administered to patients with chronic renal failure without increased adverse effects 4.

Critical Safety Considerations

  • First-dose symptomatic postural hypotension is a significant risk, occurring in approximately one-third of patients after the initial 1 mg dose 2, 3.

  • Monitor blood pressure in both supine and standing positions, particularly after the first dose and with each dose escalation 2.

  • Renal function should be monitored during chronic administration, as small reductions in glomerular filtration rate (approximately 13%) may occur, though effective renal plasma flow is generally preserved 2, 3.

Renal Effects and Benefits

  • Doxazosin treatment in chronic renal failure patients has been associated with decreased proteinuria (from 1.8 mg/day to 1.3 mg/day) and potential renal protective effects 4.

  • Some studies show improvement in glomerular filtration and decreases in plasma BUN and creatinine levels with blood pressure control 4.

  • The reduction in proteinuria correlates positively with mean blood pressure reduction (r=0.048, p=0.007) 4.

References

Research

Doxazosin in renal impairment.

Journal of human hypertension, 1990

Research

Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure.

Hypertension research : official journal of the Japanese Society of Hypertension, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.